Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New acne diagnoses linked to increased MDD risk

In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population.

Read More »

St. Jude Children’s Research Hospital to develop $412 million advanced research center to propel discovery and scientific breakthroughse

A new era of scientific advancement is emerging at St. Jude Children’s Research Hospital with the development of a $412-million advanced research center, the institution announced.

Read More »

Data Shows Long-Term Skin Clearance With Tremfya

New data from the VOYAGE 2 club incalculable trial demonstrated high efficacy response rates were achieved with continuous Tremfya (guselkumab) treatment versus withdrawal.

Read More »

Otezla Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers

Celgene Corporation announced that data from the phase III RELIEF clinical trial of Oteza (apremilast) in patients with active Behçet’s Disease showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily versus placebo through week 12.

Read More »

Biosimilar CT-P13 comparable to reference infliximab and adalimumab in highly anticipated real-world study

PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy.

Read More »

FDA clears AstraZeneca’s lung cancer immunotherapy

The U.S. FDA granted approval for expanded use of AstraZeneca‘s immunotherapy drug Imfinzi to treat non-small cell lung cancer whose tumors can not be surgically removed.

Read More »

Gilead wins hepatitis C drug patent verdict reversal

A federal judge in Delaware overturned a jury’s verdict requiring Gilead to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co.

Read More »

Agenda 2018 Special Feature: The song remains the same

The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.

Read More »

Agenda 2018: Choose your own adventure

Med Ad News asked its sources what are some of the key industry trends for 2018.

Read More »

Agenda 2018: The AMAZON-IFICATION of health is here

It’s not a new trend. For years, there has been massive speculation on the many ways Amazon could be getting into healthcare. But if you look past the hype, beyond Amazon’s theoretical intentions, and focus more closely on today’s consumer, there is a colossal healthcare trend underway even without Amazon getting in on the game. One can learn a lot from the trend of Amazon’s influence on the business of doing business. So let’s take a closer look …

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom